ABBV: AbbVie Beats Street on Soaring Humira Sales

Pharmaceutical-maker AbbVie posted first-quarter sales that beat estimates on surging sales of its Humira drug, sending ABBV stock higher. More 

Grass Pollen Allergy? New Grastek Pill From Merck Hits Shelves Soon

Merck says the U.S. Food and Drug Administration has approve the release of its Grastek grass pollen allergy drug, which will launch later this month. More 

Pharmaceuticals Deals: QCOR Gets a Big Premium, Roche Goes Shopping

Monday's big pharmaceuticals deals included Mallinckrodt buying Questcor for $5.6B -- a 27% premium to QCOR stock -- and Roche picking up Ranbaxy. More 

4 Ways Obamacare Will Affect Stocks

Obamacare is here to stay. That's good for some stocks, and horrible for others. Here's a look at the winners and losers. More 

INSM: Insmed Stock Sinks on Study Fail

Insmed announced that a Phase II study of a leading product candidate failed to meet its primary goals, sending INSM stock down sharply. More 

SNTA: Synta Pharmaceuticals Soars on Breast Cancer Treatment News

Synta Pharmaceuticals reported positive interim results from a study of its breast cancer drug, sending SNTA stock up sharply. More 

OXGN: OXiGENE Stock Soars on Ovarian Cancer Study Results

After OXiGENE announced favorable results from a Phase 2 clinical drug trial, OXGN shares doubled in value. More